Holen Sie sich die Stockscreener-App
1.01
3.81%
-0.04
Handel nachbörslich:
1.02
0.01
+0.99%
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance
ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180 - TradingKey
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance
ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - marketbeat.com
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com
ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com
ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - Quiver Quantitative
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - GuruFocus
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ADC Therapeutics SA (ADCT) Stock News Today - TradingKey
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - Morningstar
ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday - marketbeat.com
BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics SA (ADCT) Income Statement - TradingKey
ADCT|ADC Therapeutics SA|Price:1.130|Chg%:+0.005 - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADCT|ADC Therapeutics SA|Price:1.139|Chg%:-0.000 - TradingKey
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics SA (ADCT) Cash Flow - TradingKey
ADC Therapeutics SA (ADCT) Balance Sheet - TradingKey
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review
ADC Therapeutics (ADCT) Holds Steady at $1.35 as Key Support and Resistance Levels NarrowPairs Trade - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review
ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - Moomoo
Biocytogen and Whitehawk partner to develop ADCs - Pharmaceutical Technology
The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment - ad-hoc-news.de
Novartis finally enters the ADC field with an unprecedented technology - Agefi.com
ADC Therapeutics Grants One-Time Retention Awards to Executives - TipRanks
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares - Stock Titan
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer - Stock Titan
ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award - Stock Titan
ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing - Stock Titan
Executive retention awards approved at ADC Therapeutics (NYSE: ADCT) - Stock Titan
ADC Therapeutics Announces New Employee Inducement Grant - AOL.com
0.79%
5.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):